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Abstract 
Purpose: To compare the effects of two states of polymer/polymer blending (dry and 
aqueous/lyophilized) of locust bean gum with Eudragit® E100 and sodium carboxymethylcellulose on 
swelling and drug (levodopa) release from their tablet matrices. 
Methods: Sodium carboxymethylcellulose (SCMC), Eudragit® (E100) and locust bean (LB) were 
blended in their dry (as purchased) state or modified by aqueous blending and subsequent lyophilization 
prior to use as tablet matrices. The tablets were evaluated for swelling and in vitro drug release. 
Furthermore, in vivo absorption was predicted from the in vitro release data by convolution method.  
Results: E100 matrices exhibited little or no swelling while the matrices of SCMC and LB and their 
blends exhibited a degree of swelling > 180 %. Aqueous blending and lyophilization modulated the rate 
of release from matrices formulated with LB, SCMC and their polymer/polymer blends. Drug release 
profiles of the lyophilized polymer/polymer blends matrices were dissimilar to those of the dry 
polymer/polymer blends. Formulations F1aq, F2aq and F3aq exhibited fairly uniform absorption in the 
first 8 h, indicating the possibility of producing a steady delivery of drug.   
Conclusion: Polymer blending of LB, SCMC and E100, achieved by aqueous blending and 
lyophilization, enhances the performance of the matrices thereby exhibiting controlled levodopa release 
with no burst effect and the tablets retained their three-dimensional network.  
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Polymers form the integral aspect of drug 
delivery. They are used as drug carriers, having 
drug delivery properties that can be utilized for 
the administration of drugs. Prolonged delivery of 
drugs reduces frequency of dosing, prevents 
dose dumping which poses significant adverse 
effects, and enhances patient’s adherence. 
Controlled release formulations over a prolonged 
period are paramount for drugs that are rapidly 
metabolized and eliminated from the body after 
administration [1].  
 
A host of polymers are flexible and can be 
modified or tailored to achieve the desired 
effects. Xanthan gum [2,3], guar gum [4,5], gum 
Arabic [6,7], tragacanth [8], gellan gum [9,10], 
locust bean gum [11,12] are some of the natural 
polymers that have already been explored in the 
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pharmaceutical field for their role in drug delivery 
systems. The three main mechanisms that 
influence the release of drug from biodegradable 
natural polymeric systems are diffusion, swelling 
and erosion. Locust bean (LB) as purchased is a 
poor direct compressible polymer. When directly 
compressed, locust bean matrix disintegrates in 
a medium resulting in an initial burst release; and 
then, the particles are held together providing a 
controlled release subsequently.   
 
Consequently, this study sought to prevent burst 
release by blending locust bean with two other 
polymers (Eudragit E100 and SCMC). In a prior 
study, the physicomechanical properties of the 
tablet matrices formulated with blends of LB, 
E100 and SCMC were evaluated, as these can 
influence release of incorporated drug. It was 
found that blending locust bean with other 
polymers provided harder, more resilient and 
denser matrices. It is envisaged that based on 
the modified physicomechanical properties, the 
swelling and drug release will also be modified. 
Therefore, the current study elucidates the use of 
polymer-polymer blending technique to modulate 
the release of drug, levodopa from locust bean 
gum and the outcome of dry and aqueous 
blending on the swelling and release properties 






Eudragit® E100 (Evonik Röhm GmbH & Co. KG, 
Darmstadt, Germany), sodium 
carboxymethylcellulose (SCMC, Fluka 
Biochemika, Medium viscosity) locust bean, 
barium sulphate, pullulan, levodopa (Sigma-
Aldrich Inc., Steinheim, Germany), acetic acid 
glacial, hydrochloric acid (Rochelle Chemicals, 
Gauteng, South Africa), silica (Saarchem, 
Krugersdorp, South Africa), magnesium stearate 
(Merck Chemicals (PTY) LTD, Gauteng, South 
Africa).  
 
Blending of polymers 
 
The polymer/polymer blends were prepared as 
described in the prior study. Briefly, SCMC, 
Eudragit® (E100) and locust bean (LB) were 
employed individually as well as in combination 
of the three in dry and modified (aqueous 
blending and subsequent lyophilization) states. 
For aqueous blending method, 4.2 g of SCMC 
was dissolved under agitation in 50 mL of water 
and thereafter lyophilized. Aqueous/lyophilized 
states of E100 and LB were individually prepared 
using the same weight as that of SCMC and 
volume of water. The dry blend of the three 
polymers were obtained by uniformly mixing the 
polymers (SCMC, E100 and LB). The modified 
state of the tripolymer was achieved by first 
dissolving the polymers individually as described 
above. Thereafter, a solution of E100 was added 
into that of SCMC and was agitated using a 
magnetic stirrer for 2-3 h. Then LB was added 
and agitated for 15 min and subsequent 
lyophilisation was undertaken. The tripolymer 
blending was done in ratios 1:1:0.5; 1:0.5:1 and 
1:1:1 of E100, LB and SCMC respectively. At the 
end of the lyophilisation process, the 
polymers/polymer blends were milled for 
subsequent formulation of tablet matrices by 
direct compression.  
 
Formation of tablet matrices by direct 
compression  
 
Formation of tablet matrices by direct 
compression was also undertaken as described 
also in prior study. Each tablet formulated 
comprised of levodopa (100 mg), pullulan as 
adhesive (100 mg), barium sulphate as a high 
density salt (234 mg), Magnesium stearate as 
lubricant (10 mg), silica as glidant (55 mg) and 
polymer/polymer blends (500 mg). These 
materials were mixed and compressed using a 
hydraulic tablet press (Carver Industries Inc. 
Wabash, In, USA) at 29.4 KN. With regards to 
the polymer/polymer blends, there were two 
batches: One batch employing the 
polymer/polymer blend in its dry state and the 
second batch with the polymer/polymer blend in 
its modified state.  
 
Assessment of the degree of swelling of the 
tablet matrices and their blends 
 
The degree of swelling was undertaken by 
gravimetric method. The matrices were weighed, 
and dropped into pre-weighed wired baskets. 
Thereafter, the baskets were submerged in 100 
mL of 0.1 N HCl and placed in a shaker bath 
(Orbital Shaker incubator, LM-530, laboratory & 
scientific equipment Co. (PTY) LTD, Cape Town, 
South Africa) at 37 oC. Increase in weight was 
determined by weighing the tablets and the 
baskets at time intervals over 24 h after blotting 
out the medium (0.1 N HCl) each time. The 
degree of swelling was determined using Eq 1. 
 
Degree of swelling = (Wt-Wo)/Wo …… (1) 
 
Where Wt is the weight of the tablet at time t, and 
Wo is the weight of tablet at time zero. 
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In vitro drug release studies of the tablet 
matrices of polymers and their blends 
 
Levodopa release from the matrices was 
evaluated using USP apparatus II dissolution 
system (Erweka DT 700, Erweka GmbH, 
Heusenstamm, Germany) at 37 ± 0.5 °C and 50 
rpm and the dissolution medium was 900 mL of 
0.1 N HCl. Samples were withdrawn at pre-
determined periods and the same volume 
withdrawn was replaced each time with fresh 
medium in order to retain sink conditions. 
Furthermore, the quantities of levodopa released 
were quantified using a spectrophotometer 
(LAMBDA 25 UV/Vis spectrophotometer, 
PerkinElmer, Massachusetts, USA) at 280 nm. 
 
Data analysis  
 
Basic statistics, such as standard deviation was 
used to analyze the results while mathematical 
models like zero and first order kinetics, Higuchi 
and Korsmeyer-Peppas equations as well as the 
difference factor f1 and similarity factor f2 were 
used to evaluate the drug release profiles using 
DD Solver. Microsoft Excel and PK Solver were 
used for computation of predicted in vivo 





Degree of swelling of the tablet matrices of 
polymers/polymer blends 
 
Figure 1 shows the various % degrees of 
swelling exhibited by the formulations. LBp 
exhibited the highest swelling, followed by F1p, 
while F2p exhibited the least swelling. After 
‘swellability’ testing, the samples were left in the 
solvent for three months in a shaker incubator 
and tablets prepared with lyophilized polymers 
remained swollen and the three-dimensional 
network was retained, though traces of surface 
erosion were observed. However, although their 
three-dimensional network was sustained, they 
were very soft to touch. 
 
In vitro drug release and prediction of in vivo 
absorption  
 
E100p and E100aq did not modulate the release 
of levodopa from the tablet matrices and the total 
release of levodopa occurred within two hours. 
Tablets prepared with LBp released more than 
50 % of levodopa in < 2 h, while those containing 
LBaq released only about 20 % (Figure 2a). At 
the 12th hour, tablets containing LBaq released 
75 % while those containing LBp released 99.72 
at the 7th hour. Furthermore, the tablets 
containing LBaq did not lose their three-
dimensional network throughout the study. In 
addition, the rate of release from tablets of 
SCMCaq was also modulated. Tablets containing 
SCMCp, released over 90 % of drug by the 12th 
hour, while the tablets containing SCMCaq 
released about 58 % only, retaining its three-
dimensional network. Drug release from the 
modified state polymer blends was also 
modulated in comparison to the dry blending of 
the polymers (Figure 2b). The polymer matrices 
were compared on the basis of time taken for 50 
% release (T50), and for the single polymer 
matrices, the order was SCMCaq (9.72 h) > 
LBaq ( 6.17 h) > SCMCp (3.95 h) > LBp (0.69 h) 
> E100aq (0.63 h) > E100p (0.50 h). The T50 of 
the tripolymer blends was in the order F1aq (8.7 
h) > F2aq (8.2 h) > F3aq (7.8 h) > F2p (5.3 h) > 
F1p (4.0 h) > F3p (3.9 h). 
 
In order to predict the in vivo absorption of 
levodopa from the in vitro drug release data, the 





 Figure 1: Percentage degree of swelling of the tablet matrices of polymers/polymer blends 
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half-life (1.5 h) and oral bioavailability (0.44) – 
were obtained from FDA published data  [13]. 
We worked on the assumption that a carboxylase 
inhibitor such as carbidopa was co-administered 
with levodopa. Microsoft Excel was used for the 
computation to obtain plasma concentrations 
over time. Sigma plot was used to plot the 
concentration-time profiles while PK Solver was 
used to determine the pharmacokinetic 
parameters. Qureshi in his publication presented 
a simple and practical convolution technique, 
using Microsoft Excel which was used in this 
study to compute the plasma concentrations of 
the formulations [14]. Figures 2c and d depict the 
predicted plasma concentration-time profiles of 
the formulations of polymer/polymer blends. 
 
Figure 3 shows samples of digital images of loss 
and retain of 3D network by the dry state and 


















































































                
Figure 2: (a) In vitro drug release profiles tablet matrices of the native polymers in their dry and lyophilized 
states; Key: - SCMCaq; - SCMCp;  - E100aq;  - E100p;  - LBaq; - LBp; (b) In vitro drug release 
profiles tablet matrices of the polymer blends in their dry and lyophilized states; Key: - F1aq; - F1p;  - 
F2aq;  - F2p; - F3aq; - F3p; (c) Predicted plasma concentration-time profiles for the native polymers – 
CMC and LB - and their lyophilized; Key: - SCMCaq; - SCMCp;  - LBaq;  - LBp and; (b) Predicted 
plasma concentration-time profiles for formulations of polymer blends and their lyophilized over 24 hours; and 
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Figure 3: Digital images of (a) SCMCp after dissolution testing and; (b) F2aq after dissolution testing. The 
physical blends lost their 3D network while the wetted and lyophilized retained their 3D network 
 
Table 1 reveals the predicted pharmacokinetic 
parameters and the half-life of levodopa. LBp has 
the highest value for Cmax. Formulations of the 
modified state polymer/polymer blends produced 
lower Cmax. However, the concentrations were 
still within optimal response. 
 
Mathematical modeling of in vitro drug 
release profiles 
 
In vitro drug release profiles of the native 
polymers and their blends were fitted into zero 
order, first order, Higuchi and Korsmeyer-Peppas 
to determine the best fit for each formulation. The 
best fit model for the formulations was 
Korsmeyer-Peppas model except for F1p and 
F3p matrices which followed first order pattern as 
indicated in Table 2. Kormeyer-Peppas equation 
is used to ascertain the possible drug release 
mechanisms from tablet matrices. Kormeyer-
Peppas equation takes into account the 
structural and geometrical characteristics of the 
tablet matrix represented by K in equation 2:  
 
Qt/Q∞ = Ktn ……….. (2) 
 
n is the release exponent and can be obtained by 
plotting log of percentage released against log of 
time as in Eq 3.  
 
Log [Qt/Q∞] = Log K + nLog t.................  (3) 
 
The pairwise procedures, difference factor f1 and 
similarity factor f2, were employed to compare 
the drug release profiles, using the dry state 
polymer/polymer blends as the reference 
products and the modified state polymer/polymer 
blends as the test products. The results are 
indicated in Table 3. 
 





 SCMCaq SCMCp LBaq LBp F1aq F1p F2aq F2p F3aq F3p 
Cmax (ng/mL) 51.79 107.28 76.51 299.36 58.59 103.47 61.63 80.31 63.35 104.17 
Tmax (h) 2.00 3.00 3.00 1.00 4.00 3.00 3.00 4.00 3.00 3.00 
T1/2 (h) 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.5 1.50 
AUC (ng/ml*h) 659.14 1090.58 770.85 1172.78 692.05 989.88 712.81 960.65 715.95 1023.23 
MRT (h) 7.54 7.23 6.64 4.53 7.28 6.61 7.27 7.30 7.07 6.76 
Vz/F ((mg)/(ng/ml))  0.33 0.20 0.28 0.18 0.31 0.22 0.03 0.23 0.30 0.21 
Cl/F (mg)/(ng/ml)/h) 0.15 0.09 0.13 0.09 0.14 0.10 0.14 0.10 0.14 0.10 
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Table 2: Mathematical modelling of drug release profiles of the formulations 
 
Formulation First order (FO) Zero order (ZO) Higuchi (HI) Korsmeyer-Peppas (KP) Best fit 
Model 
K1 r2 K0 r2 KH r2 KKP  
(h-n) 
r2 n  
CMCaq 0.073 0.9712 5.373 0.8823 15.001 0.9425 10.458 0.9964 0.68 KP 
CMCp 0.177 0.9787 9.337 0.8558 26.131 0.9470 18.952 0.9927 0.66 KP 
E100aq - - - - - - - - - - 
E100p - - - - - - - - - - 
LBaq 0.112 0.9513 7.004 0.6650 19.833 0.9902 17.743 0.9980 0.56 KP 
LBp 1.101 0.0905 12.316 -19.428 36.962 -4.9971 76.416 0.6762 0.11 KP 
F1aq 0.084 0.9742 5.880 0.8458 16.473 0.9578 12.232 0.9986 0.65 KP 
F1p 0.176 0.9989 9.122 0.7466 25.729 0.9643 21.220 0.9845 0.60 FO 
F2aq 0.087 0.9796 6.036 0.8540 16.899 0.9558 12.400 0.9991 0.66 KP 
F2p 0.138 0.9893 8.138 0.8933 22.702 0.9401 15.519 0.9992 0.69 KP 
F3aq 0.091 0.9760 6.203 0.8241 17.406 0.9641 13.319 0.9987 0.64 KP 
F3p 0.180 0.9956 9.253 0.7550 26.085 0.9702 21.461 0.9909 0.60 FO 
 
Table 3: Pairwise comparison between the matrices of the dry state and modified state polymer/polymer blends 
 
Reference vs test Difference factor f1 Similarity factor f2  
CMCp vs CMCaq 42.44 28.40 Reject 
LBp vs LBaq 50.63 16.25 Reject 
F1p vs F1aq 39.19 32.36 Reject 
F2p vs F2aq 25.08 42.42 Reject 




Gravimetric determination of swelling without 
disturbing or removing the tablets was effective 
since the tablets remained fairly intact throughout 
the study. The use of basket made this possible 
as the tablets were weighed in the basket. 
However, SCMCp and the dry polymer blends 
underwent a measure of dissolution/erosion. This 
is due to the fact that E100 is not a swellable 
polymer, rather it dissolves in acidic medium and 
SCMC matrices also undergoes a bit of 
dissolution in aqueous medium. The tablets 
prepared with LBp disintegrated almost 
immediately it got in contact with the solvent, 
thereby losing their shapes. However, the 
particles were packed and swelling was 
measurable (403.15 %).  
 
It is envisaged that the degree of swelling was 
higher for LBp due to increased surface area and 
porosity by disintegration of tablets which 
increased the rate of solvent penetration and 
hence rate of swelling. Furthermore, it is 
envisaged that the degree of swelling was less 
with modified state polymer/polymer blends due 
to the presence of bound water leading to less 
sites for water-polymer interactions during 
‘swellability’ tests. 
 
E100 is a non-viscous and non-swellable 
polymer which is also not suitable for controlled 
and prolonged release. This remained the case 
after aqueous blending and lyophilization. 
However, aqueous blending and lyophilization 
modulated the rate of release from LB and 
SCMC matrices (Fig. 2a and b). Lyophilization 
prevented burst release experienced with directly 
compressed tablets formulated with LBp (Fig. 
2a). Consequently, LBaq exhibited an enhanced 
drug delivery property such that the rate of drug 
release from the polymer matrix is controlled and 
more linear, indicating that incorporated drugs 
can be delivered at a constant rate over a 
prolonged period. Wang et al [15] also observed 
that lyophilization eliminated burst release of 
bovine serum albumin from the microspheres as 
compared to the vacuum-dried microspheres. In 
addition, matrices of the modified state 
polymer/polymer blends were harder than dry 
state polymer/polymer blends (results not 
shown). Studies have explicated that the harder 
the tablets, the slower the drug release and vice 
versa [16,17]. Harder tablets have less voids and 
pores and so the rate of drug release is reduced 
due to reduced channels of transport across the 
tablet matrix. Less voids and pores decrease the 
rate of water ingress into the matrix, which 
decreases rate of solubility and diffusion of drug 
out of the matrix.  
 
Prediction of in vivo absorption from in vitro drug 
release enables a product developer to have an 
insight of the possible liberation and absorption 
patterns of the product. The rate and extent of 
liberation of the drug from the matrix influences 
the rate of dissolution of drug and subsequent 
rate and extent of absorption of the drug into the 
systemic circulation. Dose dumping will lead to a 
Ngwuluka et al 
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high concentration in the plasma at the period of 
release from the matrix.  
 
A moderate rate of release from the matrix will 
lead to a moderate concentration of the drug in 
the plasma. This of course does not take into 
consideration drugs that are highly metabolized. 
Therefore, during products development, 
utilization of in vitro drug release data can assist 
the developer to determine if the rate of release, 
dissolution and subsequent absorption will attain 
the desired and safe therapeutic level. 
Furthermore, prediction will give insight into the 
completeness or incompleteness of absorption, 
erratic or stable absorption and the product 
developer may decide to move to the next step of 
development or re-formulate. Therefore, in vitro-
in vivo correlation (IVIVC), does not only 
validates the in vitro drug release test but also 
affords some ethical and economic benefits such 
as reduction in the number of in vivo studies 
which in turn speeds up products development 
[14]. In this study, a convolution method was 
employed. This is a process of obtaining the drug 
concentration-time profile from the in vitro drug 
release data. However, the pharmacokinetics 
parameters, such as the volume of distribution, 
the half-life and the oral bio-availability of the 
drug are required. These parameters are 
characteristic to the drug and are not influenced 
by the product/dosage form. 
 
The range (based on patients’ variation) of mean 
plasma concentration to produce optimal 
response is 0.79-11.16 ng/mL (2.5–35.5 nmol/ml) 
[18]. The predicted concentrations over 12 h 
were over the above concentration range, 
indicating that the formulations may produce the 
therapeutic levels for at least 12 h (Fig. 2c and 
d). The challenge will be the gastric residence 
time which determines if levodopa being a 
narrow absorption window drug is made 
available at its site of absorption for at least 12 h. 
However, this is envisaged to have been tackled 
in the formulations as they were prepared to be 
gastroretentive – highly dense and swellable.  
The formulations F1aq, F2aq and F3aq exhibited 
a fairly uniform absorption in the first 8 h 
indicating the possibility of producing a constant 
delivery of levodopa.   
 
In vitro drug release profiles of the native 
polymers and their blends were fitted into zero 
order, first order, Higuchi and Korsmeyer-
Peppas, in order to assess the best fit for each 
formulation. For a cylindrical matric, if n = 0.45, 
the release mechanism is Fickian diffusion, non-
Fickian release or anomalous transport if 
0.45<n<0.89, case II transport or zero-order 
release if n = 0.89, and super case II transport if 
>0.89 [19]. The release exponent n, for all the 
formulations except LBp displayed non-Fickian 
release or anomalous transport, indicating that 
the patterns of release from the matrices were a 
combination of release mechanisms other than 
diffusion.  
 
Although from Table 2A, it would imply that 
Kormeyer-Peppas is the best fit for LBp; 
however, it falls short in describing the 
mechanism of drug release from LBp matrices. 
This is due to the fact that n = 0.11 which is less 
than 0.45 implying that it falls out of 
specifications of Korsmeyer-Peppas drug release 
model. Furthermore, the further away correlation 
co-efficients (regression), r is from 1, the less 
perfect the utilized model is. While LBp matrices 
disintegrated on immediate contact with the 
dissolution medium releasing 76 % of the drug 
within the first hour, LBaq matrices released only 
16.7 %. Hence, directly compressed LBp 
matrices cannot be considered as controlled 
release. The dose dumping can be modulated by 
using other techniques such as granulation or 
using its lyophilized form.   
 
Two drug release profiles are stated to be 
similar, if f1 values are lower than 15 (acceptable 
range of similarity is 0-15), and f2 values are 
greater than 50 (acceptable range of similarity is 
50-100) [20, 21]. From Table 2B, it can be 
observed that drug release profiles of the 
lyophilized polymer/polymer blends matrices 
were dissimilar to those of the dry 
polymer/polymer blends. Consequently, the 
products are bio-inequivalent and cannot be 
used interchangeably. Furthermore, it indicates 
that the modified state blending employed in this 
study, can modulate drug release. The 
modulation was significant such that the 
reference and test products may not exhibit 
similar rate and extent of absorption when 





Native locust bean gum is a poor directly 
compressible agent. However, it is usually used 
in tablet formulation by wet granulation method 
or polymer-polymer blending.  Modified state 
blending achieved by aqueous blending and 
lyophilization modified the gum, making it directly 
compressible and exhibiting controlled drug 
release with no burst effect with the tablets 
retaining their three-dimensional network. The 
matrices had a more controlled release of 
levodopa than those of the dry state polymer 
blends and retained their three-dimensional 
network. 
Ngwuluka et al 
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